|
WO2017136049A1
|
|
Compositions for linking dna-binding domains and cleavage domains
|
|
US2017211075A1
|
|
Targeted disruption of the t cell receptor
|
|
AU2016216543A1
|
|
Methods And Compositions For Targeted Single-Stranded Cleavage And Targeted Integration
|
|
US2016369262A1
|
|
Nuclease-mediated regulation of gene expression
|
|
US2016326548A1
|
|
Methods and compositions for increasing transgene activity
|
|
WO2016118726A2
|
|
Methods and compositions for identification of highly specific nucleases
|
|
US2016168593A1
|
|
Methods and compositions for enhancing targeted transgene integration
|
|
US2016060656A1
|
|
Method of treating mucopolysaccharidosis type I or II
|
|
WO2016019144A2
|
|
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
|
WO2016014837A1
|
|
Gene editing for hiv gene therapy
|
|
US2016024474A1
|
|
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
|
WO2015188065A1
|
|
Methods and compositions for nuclease design
|
|
CA2947622A1
|
|
Methods and compositions for prevention or treatment of a disease
|
|
US2015335708A1
|
|
Methods and compositions for treating huntington's disease
|
|
US2015307561A1
|
|
Engineered transcription activator like effector (TALE) proteins
|
|
WO2015153760A2
|
|
Methods and compositions for prevention or treatment of a nervous system disorder
|
|
WO2015143046A2
|
|
Methods and compositions for regulation of zinc finger protein expression
|
|
AU2015201300A1
|
|
Methods and Compositions For Inactivating Glutamine Synthetase Gene Expression
|
|
AU2015200431A1
|
|
Linear Donor Constructs For Targeted Integration
|
|
US2015164954A1
|
|
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
